Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908611 | 0.96 | KDM4E (0.40) | KDM4EMEN1KMT2ABCHEACHE | |
| SCHEMBL2911110 | 0.81 | KDM4E (0.46) | KDM4EMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL7837160 | 0.78 | PDE3A (0.47) | KDM4EPOLBPSMB5ALDH1A1PDE3B | |
| SCHEMBL2907694 | 0.76 | MAOA (0.43) | KDM4EPOLBPSMB5PDE3BPDE3A | |
| SCHEMBL2905838 | 0.76 | MAOA (0.43) | KDM4EPOLBPSMB5ALDH1A1TDP1 | |
| SCHEMBL2905210 | 0.76 | KDM4E (0.54) | KDM4EMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL2905651 | 0.76 | USP2 (0.41) | KDM4EMEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2910847 | 0.74 | KDM4E (0.40) | KDM4EMEN1KMT2APSMB5ACHE | |
| SCHEMBL2910450 | 0.74 | KDM4E (0.54) | KDM4EMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL13792058 | 0.73 | MAOA (0.40) | KDM4EPSMB5ALDH1A1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1400510-A1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6632810-B2 | Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation | KOWA CO., LTD. (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | KDM4E 2052/4885MEN1 1989/4885KMT2A 916/4885 |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | KDM4E 2052/4885MEN1 1989/4885KMT2A 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.